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The pathophysiology of chronic Graft-versus-Host Disease
(cGVHD) is complex and poorly understood. Storage of pe-
ripheral blood mononucleated cells (PBMC) for research in
patient cohorts is vital. However, conventional peripheral
blood draws are often insufﬁcient for larger scale immu-
nology studies; in particular, cGVHD patients are frequently
lymphopenic, which further limits an ability to study the role
of relatively rare populations such as Treg cells. To address
this limitation, we evaluated the safety of collecting large
quantities of lymphocytes in cGVHD patients by steady-state
peripheral blood leukapheresis. In total, 132 patients with
cGVHD underwent PBMC collection for research purposes via
leukapheresis performed from 2004 to 2014 on NCI cGVHD
Natural History Protocol, NCT00092235. Various apheresis
machines were used, namely: Baxter CS3000 (n¼63, 47%),
Haemonetics MCS-P (n¼18, 14%), and Terumo SPECTRA
(n¼52, 39%). Median whole blood/anticoagulant (ACDA) ra-
tio was 12:1; median whole blood ﬂow rate (WBFR) was 60
ml/min (35-85); and median product volume was 147 ml
(59-450). Median age was 50 years (18-68). NIH cGVHD
Global scores were moderate (n¼46, 35%) or severe (n¼82,
62%). Mean absolute circulating PBMC level pre-leukaphe-
resis was 2.4 K/mL (0.3-11.6). 22 patients (17%) had an abso-
lute lymphocyte count <1.0 K/ml. A subset of patients (17/
132) had sufﬁciently low pre-leukapheresis peripheral
counts that required special approval for the procedure (Hb
<9.0 g/dL, n¼3; WBC < 3.0 K/mL, n¼5; platelets < 120 K/mL,
n¼9). A two-arm continuous ﬂow apheresis procedure was
used in 108 patients (81%) whereas a one-arm procedurewas
used in 25 patients (8%). Only nine patients underwent leu-
kapheresis via central venous catheter (the remainder were
pheresed using peripheral access). 94 (71%) achieved the
goal collection of 2 x 109 PBMCs, with a mean volume pro-
cessed of 4.6 L. Median total run time was 88 minutes. Mean
number of cells collected and efﬁciencies were: (1) lym-
phocytes, 3.7 x 109, 66.5%; (2) monocytes, 1.1 x 109, 51.1%;
and (3) PBMCs: 4.8 x 109, 59.7%. Mild decreases in abso-
lute peripheral counts were observed, including (median
change 1 hour post-leukapheresis; each value signiﬁcant,
p<0.0001): Hgb: -8%; Plt: -22%; lymphocytes: -26%; and
monocytes: -17%. Grade 1 AEs (CTCAE v4.03) were experi-
enced by 21 patients (16%): hypotension (n¼1, 1%), oral
dysesthesia (n¼10, 8%), paresthesias (n¼6, 5%), anxiety (n¼1,
1%), localized bleeding (n¼2, 2%), and nausea (n¼1, 1%). In
conclusion, we found that steady-state PBMC leukapheresis
represents a safe and effective method for collecting high
numbers of immune cells in patients with moderate-to-se-
vere cGVHD.Wider utilization of leukapheresis in the cGVHD
setting should accelerate immunology research into the
pathogenesis of cGVHD, particularly relating to the role of
relatively rare cell populations.477
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Allogeneic blood and marrow transplantation for the treat-
ment of hematologic malignancies continues to be plaguedby complications such as chronic graft-versus-host disease
(cGVHD), which can occur in upwards of 50% of patients.
Standard therapy involves corticosteroid administration,
which is not always effective and impedes the patient’s re-
turn to a completely competent immune system, thus
increasing the risk of infectious complications. Extracorpo-
real photopheresis (ECP) has been successfully used to abate
cGVHD symptoms in many patients. The effect this therapy
has on lymphocyte subsets in the reconstituting immune
compartment has yet to be fully ascertained. In the pre-
sent study, we used ﬂow cytometric analysis to examine
lymphocyte subsets in patients undergoing ECP for the
treatment of cGVHD. Peripheral blood was collected from 5
patients prior to starting ECP and after 90 days of treatment.
CD4+T cell populations were analyzed for expression of
CD45RA and CCR7 to classify naïve (RA+, CCR7+), central
memory (TCM; RA-, CCR7+), effector memory (TEM; RA-,
CCR7-), and terminally differentiated effector memory
(TEMRA; RA+, CCR7-) T cells. The data reported supports pre-
vious studies which show that all CD4+ T cell populations
analyzed are altered in cGVHD patients (n¼11) compared to
healthy controls (n¼5). In particular, CD4+ TCM and naïve cells
were decreased in cGVHD patients, while CD4+ TEM and
TEMRA were elevated in these patients. Analysis of the same
subsets in cGVHD patients after 90 days of ECP treatment
revealed that the percentage of CD4+ TCMincreased above
baseline levels in the 5 cGVHD patients examined, while
CD4+ TEMRA were decreased during the same time frame. The
increase in CD4+ TCM and the decrease in CD4+ TEMRA were
statistically signiﬁcant as determined by the paired Student’s
t test. Additionally, the ratio of CD4+ TCM to TEM and CD4+ TCM
to TEMRA was calculated in patients before and after ECP
treatment. Results indicate signiﬁcantly increased ratios of
both TCM:TEMand CD4+ TCM:TEMRA in these patients as well.
This data strongly supports the role of ECP in the normali-
zation of CD4+ T cell populations in cGVHD patients.478
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While the ﬁrst-in-disease trials of GvHD prevention with
costimulation blockade add CTLA4-Ig to standard tacrolimus/
methotrexate, previous work has suggested that mTOR in-
hibition with sirolimus is more pro-tolerogenic when paired
with costimulation blockade. We have now investigated
combination CTLA4-Ig + sirolimus to prevent GvHD in the
NHP model, and have interrogated the outcomes using a
systems-based approach. Our experiments provide strong
clinical, immunologic and trancriptomic evidence for potent
synergy when CTLA4-Ig and sirolimus are combined for
GvHD prevention.
We determined the impact of the following treatments on
GvHD after haplo-identical HSCT: 1) no therapy (n¼4) 2)
CTLA4-Ig monotherapy (using belatacept, n¼3) 3) sirolimus
monotherapy (n¼4) 4) combination belatacept and
sirolimus (n¼3). To determine the relative impact of each
therapeutic approach, we monitored clinical GvHD, GvHD-
free survival, and ﬂow cytometric signs of immune activation
